Reoperation After Surgical Treatment for Benign Prostatic Hyperplasia: a Systematic Review

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Nov 29

PMID 38027158

Authors

Weixiang He

Ting Ding

Zhiping Niu

Chunlin Hao

Chengbin Li

Zhicheng Xu

Yuming Jing

Weijun Qin

Affiliations

Soon will be listed here.

Abstract

Context: Surgical treatment is important for male lower urinary tract symptom (LUTS) management, but there are few reviews of the risks of reoperation.

Objective: To systematically evaluate the current evidence regarding the reoperation rates of surgical treatment for LUTS in accordance with current recommendations and guidelines.

Evidence Acquisition: Eligible studies published up to July 2023, were searched for in the PubMed (National Library of Medicine, Bethesda, MD, USA), Embase (Elsevier, Amsterdam, the Netherlands), and Web of Science™ (Clarivate™, Philadelphia, PA, USA) databases. STATA (StataCorp LP, College Station, TX, USA) software was used to conduct the meta-analysis. Random-effects models were used to calculate the pooled incidences (PIs) of reoperation and the 95% confidence intervals (CIs).

Evidence Synthesis: A total of 119 studies with 130,106 patients were included. The reoperation rate of transurethral resection of the prostate (TURP) at 1, 2, 3, and 5 years was 4.0%, 5.0%, 6.0%, and 7.7%, respectively. The reoperation rate of plasma kinetic loop resection of the prostate (PKRP) at 1, 2, 3, and 5 years was 3.5%, 3.6%, 5.7%, and 6.6%, respectively. The reoperation rate of holmium laser enucleation of the prostate (HoLEP) at 1, 2, 3, and 5 years was 2.4%, 3.3%, 5.4%, and 6.6%, respectively. The reoperation rate of photoselective vaporization of the prostate (PVP) at 1, 2, 3, and 5 years was 3.3%, 4.1%, 6.7%, and 7.1%, respectively. The reoperation rate of surgery with AquaBeam at 1, 2, 3, and 5 years was 2.6%, 3.1%, 3.0%, and 4.1%, respectively. The reoperation rate of prostatic artery embolization (PAE) at 1, 2, 3, and 5 years was 12.2%, 20.0%, 26.4%, and 23.8%, respectively. The reoperation rate of transurethral microwave thermotherapy (TUMT) at 1, 2, 3, and 5 years was 9.9%, 19.9%, 23.3%, and 31.2%, respectively. The reoperation rate of transurethral incision of the prostate (TUIP) at 5 years was 13.4%. The reoperation rate of open prostatectomy (OP) at 1 and 5 years was 1.3% and 4.4%, respectively. The reoperation rate of thulium laser enucleation of the prostate (ThuLEP) at 1, 2, and 5 years was 3.7%, 7.7%, and 8.4%, respectively.

Conclusion: Our results summarized the reoperation rates of 10 surgical procedures over follow-up durations of 1, 2, 3, and 5 years, which could provide reference for urologists and LUTS patients.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023445780.

Citing Articles

Urethra-preserving and dorsal capsule fenestration with robot-assisted simple prostatectomy for severe LUTS in small prostate: a case report.

Wen L, Zhang Y, He Y, Yu Y, Yang B Front Surg. 2024; 11:1497556.

PMID: 39669893 PMC: 11634874. DOI: 10.3389/fsurg.2024.1497556.

alleviates testosterone-induced benign prostatic hyperplasia by inhibiting 5α-reductase activity and androgen receptor signaling pathway.

Hwangbo H, Cha H, Kim M, Ji S, Kim D, Noh J Nutr Res Pract. 2024; 18(6):793-805.

PMID: 39651318 PMC: 11621438. DOI: 10.4162/nrp.2024.18.6.793.

Residual Prostatic Tissue Mimics Anterior Wall Carcinoma of the Bladder: A Rare Complication of the Holmium Laser Enucleation of the Prostate (HoLEP).

Akkurt B, Arslan U, Akan S Cureus. 2024; 16(11):e72984.

PMID: 39640089 PMC: 11617493. DOI: 10.7759/cureus.72984.

Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study).

Kaplan S, Moss J, Freedman S Prostate Cancer Prostatic Dis. 2024; 27(3):531-536.

PMID: 38684918 PMC: 11319191. DOI: 10.1038/s41391-024-00833-z.

References

Chen C, Lin S, Chiang P . Outcome of GreenLight HPS laser therapy in surgically high-risk patients. Lasers Med Sci. 2012; 28(5):1297-303. DOI: 10.1007/s10103-012-1234-9. View

Pfitzenmaier J, Gilfrich C, Pritsch M, Herrmann D, Buse S, Haferkamp A . Vaporization of prostates of > or =80 mL using a potassium-titanyl-phosphate laser: midterm-results and comparison with prostates of <80 mL. BJU Int. 2008; 102(3):322-7. DOI: 10.1111/j.1464-410X.2008.07563.x. View

Liu X, Yuan F, Xue Md B . GreenLight XPS 180-W Laser Vaporization of Prostate in High-Risk Elderly Patients: A Single-Center Experience. Photobiomodul Photomed Laser Surg. 2020; 38(6):380-384. DOI: 10.1089/photob.2019.4735. View

Hueber P, Ben-Zvi T, Liberman D, Bhojani N, Gautam G, Deklaj T . Mid term outcomes of initial 250 case experience with GreenLight 120W-HPS photoselective vaporization prostatectomy for benign prostatic hyperplasia: comparison of prostate volumes < 60 cc, 60 cc-100 cc and > 100 cc. Can J Urol. 2012; 19(5):6450-8. View

Keoghane S, Lawrence K, Gray A, Doll H, Hancock A, Turner K . A double-blind randomized controlled trial and economic evaluation of transurethral resection vs contact laser vaporization for benign prostatic enlargement: a 3-year follow-up. BJU Int. 2000; 85(1):74-8. DOI: 10.1046/j.1464-410x.2000.00407.x. View

Tan A, Gilling P, Kennett K, Fletcher H, Fraundorfer M . Long-term results of high-power holmium laser vaporization (ablation) of the prostate. BJU Int. 2003; 92(7):707-9. DOI: 10.1046/j.1464-410x.2003.04474.x. View

Madersbacher S, Lackner J, Brossner C, Rohlich M, Stancik I, Willinger M . Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. Eur Urol. 2005; 47(4):499-504. DOI: 10.1016/j.eururo.2004.12.010. View

Hill B, Belville W, Bruskewitz R, Issa M, Perez-Marrero R, Roehrborn C . Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol. 2004; 171(6 Pt 1):2336-40. DOI: 10.1097/01.ju.0000127761.87421.a0. View

Gravas S, Laguna P, Kiemeney L, de la Rosette J . Durability of 30-minute high-energy transurethral microwave therapy for treatment of benign prostatic hyperplasia: a study of 213 patients with and without urinary retention. Urology. 2007; 69(5):854-8. DOI: 10.1016/j.urology.2007.01.070. View

10.

Varkarakis I, Kyriakakis Z, Delis A, Protogerou V, Deliveliotis C . Long-term results of open transvesical prostatectomy from a contemporary series of patients. Urology. 2004; 64(2):306-10. DOI: 10.1016/j.urology.2004.03.033. View

11.

Hammadeh M, Madaan S, Singh M, PHILP T . A 3-year follow-up of a prospective randomized trial comparing transurethral electrovaporization of the prostate with standard transurethral prostatectomy. BJU Int. 2000; 86(6):648-51. DOI: 10.1046/j.1464-410x.2000.00879.x. View

12.

Yang B, Shen B, Liu W, Cheng Y, Shao Y, Qian J . Medium-term Clinical Efficacy and Complications of Plasmakinetic Enucleation of the Prostate Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. Urology. 2022; 164:204-210. DOI: 10.1016/j.urology.2022.01.013. View

13.

Gross A, Orywal A, Becker B, Netsch C . Five-year outcomes of thulium vapoenucleation of the prostate for symptomatic benign prostatic obstruction. World J Urol. 2017; 35(10):1585-1593. DOI: 10.1007/s00345-017-2034-4. View

14.

Castellani D, Di Rosa M, Gasparri L, Pucci M, Dellabella M . Thulium Laser Vapoenucleation of the Prostate (ThuVEP) in Men at High Cardiovascular Risk and on Antithrombotic Therapy: A Single-Center Experience. J Clin Med. 2020; 9(4). PMC: 7231078. DOI: 10.3390/jcm9040917. View

15.

Bach T, Netsch C, Pohlmann L, Herrmann T, Gross A . Thulium:YAG vapoenucleation in large volume prostates. J Urol. 2011; 186(6):2323-7. DOI: 10.1016/j.juro.2011.07.073. View

16.

Tao W, Xue B, Zang Y, Sun C, Yang D, Zhang Y . The application of 120-W high-performance system GreenLight laser vaporization of the prostate in high-risk patients. Lasers Med Sci. 2012; 28(4):1151-7. DOI: 10.1007/s10103-012-1212-2. View

17.

Ahyai S, Lehrich K, Kuntz R . Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial. Eur Urol. 2007; 52(5):1456-63. DOI: 10.1016/j.eururo.2007.04.053. View

18.

Yamada Y, Furusawa J, Sugimura Y, Kuromatsu I . Photoselective Vaporization of the Prostate: Long-Term Outcomes and Safety During 10 Years of Follow-Up. J Endourol. 2016; 30(12):1306-1311. DOI: 10.1089/end.2016.0522. View

19.

Lin Y, Wu X, Xu A, Ren R, Zhou X, Wen Y . Transurethral enucleation of the prostate versus transvesical open prostatectomy for large benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials. World J Urol. 2015; 34(9):1207-19. DOI: 10.1007/s00345-015-1735-9. View

20.

Gilling P, Aho T, Frampton C, King C, Fraundorfer M . Holmium laser enucleation of the prostate: results at 6 years. Eur Urol. 2007; 53(4):744-9. DOI: 10.1016/j.eururo.2007.04.052. View